EFUT [eFuture] 6-K: (Original Filing)

[FORM 6-K EFUTURE INFORMATION TECHNOLOGY INC. 8/F TopNew Tower 2 15 Guanghua Road Chaoyang District Beijing 100026, People’s Republic of China 86-10-51650988 þ Form 20-F o þ Yes Effective on August 22, 2014, Dennis O. Laing, a director and a member of the audit committee of eFuture Information Technology Inc. (the “Company”) resigned from his foregoing positions in the Company]

By | 2016-03-23T05:49:32+00:00 August 25th, 2014|Categories: Chinese Stocks, EFUT, SEC Original|Tags: , , , , , |0 Comments

EFUT [eFuture] 6-K: FORM 6-K EFUTURE INFORMATION TECHNOLOGY INC. 8/F TopNew

[FORM 6-K EFUTURE INFORMATION TECHNOLOGY INC. 8/F TopNew Tower 2 15 Guanghua Road Chaoyang District Beijing 100026, People’s Republic of China 86-10-51650988 þ Form 20-F o þ Yes Effective on August 22, 2014, Dennis O. Laing, a director and a member of the audit committee of eFuture Information Technology Inc. (the “Company”) resigned from his foregoing positions in the Company]

By | 2016-03-23T05:50:58+00:00 August 25th, 2014|Categories: Chinese Stocks, EFUT, Webplus ver|Tags: , , , , , |0 Comments

GSH [GUANGSHEN RAILWAY CO] 6-K: (Original Filing)

[(a joint stock limited company incorporated in the People’s Republic of China) (Stock Code: 00525) 2014 INTERIM RESULT ANNOUNCEMENT Company The Board of Directors of Guangshen Railway Company Limited (the “ IMPORTANT NOTICE All Directors of the Company attended the meeting of the Board to consider the 2014 interim report. The Board has decided not to distribute any interim profit] [Interim Report 2014 [ Stock Code: 00525 ] GSRC INTERIM REPORT 2014 [ Stock Code: 00525 ] IMPORTANT NOTICE All Directors of the Company attended the meeting of the Board to consider the 2014 interim report. The Board has decided not to distribute any interim profit or transfer any common reserve into share capital for the interim period of 2014.]

By | 2016-03-10T15:17:04+00:00 August 25th, 2014|Categories: Chinese Stocks, GSH, SEC Original|Tags: , , , , , |0 Comments

CBPO [China Biologic Products] 8-K: (Original Filing)

[Registered Equity Purchase Agreement Agreement Purchaser Seller This Registered Equity Purchase Agreement (this “ WHEREAS Target Company WHEREAS Capital Increase WHEREAS Target Equities WHEREAS NOW THEREFORE Section 2 Sale of Equity Interests Sale of Equity Interests 2.1 Equity Transfer Subject to the terms and conditions hereunder and satisfaction of such terms and conditions, the Seller agrees to sell to the] [Equity Exchange Agreement Agreement Guiyang Dalin Guizhou Eakan This Equity Exchange Agreement (this “ WHEREAS Guizhou Taibang WHEREAS Capital Increase WHEREAS Taibang Equities WHEREAS Acquisition SPV SPV Equities WHEREAS NOW THEREFORE Section 2 Equity Exchange Equity Exchange 2.1 Guizhou Eakan agrees to sell the Taibang Equities in exchange for the SPV Equities held by Guiyang Dalin (the “ 2.2 The] [Unregistered Equity Purchase Agreement Agreement Purchaser Seller This Unregistered Equity Purchase Agreement (this “ WHEREAS Capital Increase Target Company Shareholders Resolutions Unregistered Equities Contingent Claims Target Interests WHEREAS NOW THEREFORE Section 2 Sale of the Target Interests Sale of the Target Interests 2.1 Equity Transfer Purchase Price 2.1.1 Subject to the terms and conditions hereunder and the satisfaction of such] [FOR RELEASE August 25, 2014 China Biologic to Increase Equity Stake in Guizhou Taibang BEIJING, China – August 25, 2014 – Mr. David (Xiaoying) Gao, Chairman and Chief Executive Officer of China Biologic, commented, “Increasing our ownership position in Guizhou Taibang is a significant development for China Biologic. Since acquiring the majority stake in 2008, we have been focusing on] []

GSH [GUANGSHEN RAILWAY CO] 6-K: (a joint stock limited company incorporated in the

[(a joint stock limited company incorporated in the People’s Republic of China) (Stock Code: 00525) 2014 INTERIM RESULT ANNOUNCEMENT Company The Board of Directors of Guangshen Railway Company Limited (the “ IMPORTANT NOTICE All Directors of the Company attended the meeting of the Board to consider the 2014 interim report. The Board has decided not to distribute any interim profit] [Interim Report 2014 [ Stock Code: 00525 ] GSRC INTERIM REPORT 2014 [ Stock Code: 00525 ] IMPORTANT NOTICE All Directors of the Company attended the meeting of the Board to consider the 2014 interim report. The Board has decided not to distribute any interim profit or transfer any common reserve into share capital for the interim period of 2014.]

By | 2016-03-10T15:18:07+00:00 August 25th, 2014|Categories: Chinese Stocks, GSH, Webplus ver|Tags: , , , , , |0 Comments

CBPO [China Biologic Products] 8-K: Registered Equity Purchase Agreement Agreement Purchaser Seller This

[Registered Equity Purchase Agreement Agreement Purchaser Seller This Registered Equity Purchase Agreement (this “ WHEREAS Target Company WHEREAS Capital Increase WHEREAS Target Equities WHEREAS NOW THEREFORE Section 2 Sale of Equity Interests Sale of Equity Interests 2.1 Equity Transfer Subject to the terms and conditions hereunder and satisfaction of such terms and conditions, the Seller agrees to sell to the] [Equity Exchange Agreement Agreement Guiyang Dalin Guizhou Eakan This Equity Exchange Agreement (this “ WHEREAS Guizhou Taibang WHEREAS Capital Increase WHEREAS Taibang Equities WHEREAS Acquisition SPV SPV Equities WHEREAS NOW THEREFORE Section 2 Equity Exchange Equity Exchange 2.1 Guizhou Eakan agrees to sell the Taibang Equities in exchange for the SPV Equities held by Guiyang Dalin (the “ 2.2 The] [Unregistered Equity Purchase Agreement Agreement Purchaser Seller This Unregistered Equity Purchase Agreement (this “ WHEREAS Capital Increase Target Company Shareholders Resolutions Unregistered Equities Contingent Claims Target Interests WHEREAS NOW THEREFORE Section 2 Sale of the Target Interests Sale of the Target Interests 2.1 Equity Transfer Purchase Price 2.1.1 Subject to the terms and conditions hereunder and the satisfaction of such] [FOR RELEASE August 25, 2014 China Biologic to Increase Equity Stake in Guizhou Taibang BEIJING, China – August 25, 2014 – Mr. David (Xiaoying) Gao, Chairman and Chief Executive Officer of China Biologic, commented, “Increasing our ownership position in Guizhou Taibang is a significant development for China Biologic. Since acquiring the majority stake in 2008, we have been focusing on] []

Skip to toolbar